Gastrointestinal (GI) GVHD after allo-SCT is diagnosed on the basis of symptoms and findings in endoscopic mucosal biopsy specimens. However, GI symptoms often persist despite treatment and whether a second endoscopy may be helpful in determining the most suitable therapy is not established. We identified 31 patients with persistent diarrhea who underwent more than one endoscopic study. All cases underwent serial microbiological stool analysis and CMV-detecting assays on serum and biopsies. Of the 31 initial GI biopsies, 20 (64.5%) were classified as GVHD, two (6.5%) as GVHD with CMV, four (13%) as non-CMV infection, and five (16%) as normal or unspecific. The second GI biopsies were diagnostic of GVHD in nine cases (29%), GVHD simultaneously with CMV infection in four (13%), regenerative changes post-GVHD in five (16%), CMV infection in four (13%), and normal or unspecific in nine (29%). In 22 of the 31 patients (71%), the histological findings of the second/third endoscopic biopsies differed from the findings of the first endoscopy and led to a therapy change in 77%. In conclusion, serial GI endoscopies are of reliable diagnostic value and can impact on therapeutic decision-making for patients with persistent diarrhea after allo-SCT.
Introduction
GVHD is a frequent complication of allo-SCT and is associated with considerable morbidity and high rates of non-relapse-mortality. The gastrointestinal (GI) tract is the second most commonly involved organ in acute GVHD, with up to 50% of the patients who develop GVHD exhibiting GI involvement.
1 Nausea, watery diarrhea, loss of appetite, bloody or mucoid stools, and abdominal pain are the primary manifestations of GI GVHD. However, these symptoms and signs are also often seen in other GI diseases, including drug toxicity and enteric infections.
2,3
For example, GI conditioning-related toxicity, which can mimic histological GVHD, is prevalent within 3-4 weeks after transplantation, especially among patients receiving myeloablative conditioning regimens. In addition, mycophenolate mofetil, an immunosuppressive drug that is commonly used in non-myeloablative allo-SCT, is associated with diarrhea and GVHD-like histological features. 4 Moreover, several infectious agents such as Clostridium difficile, Candida, CMV, adenovirus, norovirus and rotavirus cause diarrhea that is clinically indistinguishable from that in GI GVHD; some of these microorganisms are also known to cause epithelial apoptosis in the gut.
2, 3, 5, 6 The diagnosis of GI GVHD is largely based on clinical features but a confirmatory endoscopic biopsy is recommended to establish this diagnosis. When there is clinical suspicion of GI GVHD, therapy must be initiated early. However, the response rate of acute GVHD to first line therapy with corticosteroids is B50%, with lower intestinal GVHD responding even more poorly than cutaneous or upper GI GVHD. 7, 8 Thus, despite the histological diagnosis of GVHD and corticosteroid therapy, diarrhea persists frequently. This may be due to therapy failure, intestinal mucosa destruction and/or the coexistence of intestinal infection. Given that these situations require entirely different management programs and the overuse of highdose systemic corticosteroids and other immunosuppressive drugs can lead to significant adverse events, the initial diagnosis should be re-evaluated before the treatment is changed. Along with exhaustive microbiological studies, a second intestinal endoscopic examination may help to determine which therapy is best for these patients. However, while several studies have addressed the diagnostic value of the first endoscopy, there is less information available regarding second or subsequent GI endoscopies.
In this study, we retrospectively identified allo-SCT patients who had persistent diarrhea despite treatment based on the first endoscopic study and who then under-went a second endoscopic study. We reviewed their endoscopic, histological, and microbiological findings and evaluated the impact of the second GI endoscopic evaluation on clinical decisions.
Patients and methods

Patients
Between January 2004 and December 2009, 75 patients had a GI endoscopic study because of clinical suspicion of GI GVHD. Thirty-one of them had two or more GI endoscopic and histological evaluations for persistent GI symptoms. Of these, 19 and 12 patients underwent two and three or more endoscopies, respectively (median 2, range 2-5). Demographic information, the hematological disease and allo-SCT data, the symptoms that prompted endoscopic evaluation, and the endoscopic and histological findings were extracted from each patient's medical records. In all cases, microbiological analyses of stools, including bacterial culture, the Clostridium difficile toxin assay, adenovirus and rotavirus Ag detection assays, and parasite examinations, were performed at the time of the endoscopic studies. CMV infection was monitored by pp65 antigenemia and/or quantitative CMV-PCR testing once or twice weekly. CMV histopathological testing was performed in each GI biopsy. The diagnosis of GI CMV disease was based on a combination of clinical symptoms, the detection of macroscopic mucosal lesions on endoscopy and a demonstration of CMV by histopathological testing of an intestinal biopsy. 9 If CMV Ag or CMV PCR levels were positive, the patients were started on preemptive therapy. Those patients whose intestinal biopsies immunostained positively for CMV were treated with gancyclovir or foscarnet.
This retrospective study was approved by our institutional ethics committee and all patients gave their signed, informed consent for both the study and the endoscopic procedures.
Endoscopic and biopsy procedures
Endoscopic procedures were performed with conscious sedation using propofol or midazolam plus remifentanil. Biopsies were obtained by using standard endoscopic forceps. Between five and ten specimens were taken at different locations on the GI tract. Platelet transfusions were administered before endoscopy at the discretion of the hematologist in cases where the platelet counts were below 30 000-50 000 per mL. The endoscopic findings were graded using the following scale: 0, normal; 1, mild to moderate edema and/or erythema; 2, edema, erythema and erosions; and 3, ulceration and/or bleeding.
The biopsy specimens were reviewed by two GI pathologists along with the clinical review by the faculty staff from the Stem Cell Transplantation Unit. Acute GVHD was diagnosed by using the previous published histological criteria for GI GVHD, namely if glandular apoptosis was observed in the absence of another inflammatory or infectious cause. 6, [10] [11] [12] Statistical analysis This study describes the endoscopic and histological findings of serial GI examinations. The accuracy, sensitivity, specificity and positive predictive value with which these endoscopies aided the diagnosis of GI GVHD were analyzed. Logistic regression was used to investigate whether endoscopic grade could predict the presence of GVHD. Statistical analysis was performed by using SPSS statistics 16.0 for Windows, Chicago, IL, USA.
Results
Patients and allo-SCT procedure characteristics are summarized in Table 1 . Eighteen (58%) patients developed cutaneous GVHD. In six and four of these patients, the cutaneous GVHD was active at the time of the first and second endoscopies, respectively. The histological diagnosis of intestinal GVHD did not correlate significantly with the presence of previous or concomitant cutaneous GVHD, although a trend was observed (P ¼ 0.11).
The most common symptom that prompted endoscopic evaluation was diarrhea with or without abdominal pain. Moreover, one patient was evaluated for digestive hemorrhage. The first endoscopy was performed at a median of 57 days (range, 16-155) after allo-SCT. The types of endoscopy performed were rectosigmoidoscopy (n ¼ 17), colonoscopy (n ¼ 9), rectoscopy (n ¼ 4) and gastroscopy (n ¼ 1). The median time from the first to the second endoscopy was 15.5 days (range, 5-98). The second GI evaluation was by rectosigmoidoscopy (n ¼ 10), colonoscopy (n ¼ 9), rectoscopy (n ¼ 5) and gastroscopy (n ¼ 7). The most common indications for the second endoscopy were persistence of diarrhea (81%) followed by GI bleeding (13%) and abdominal pain (6%). In nine patients, a third endoscopy Table 1 Characteristics of the patients and allo-SCT procedure Abbreviation: ATG ¼ anti-thymocyte globulin.
Serial gastrointestinal endoscopies after allo-SCT C Martínez et al was performed. No major bleeding events were observed after the procedures. The endoscopic and histological findings of the first, second and third endoscopies are shown in Table 2 . In the first and second endoscopies, abnormal GI mucosa was observed in 24 and 27 patients, respectively. The histological evaluation of the 31 first biopsies revealed that 20 (64.5%) were classified as GVHD, two (6.5%) as GVHD concomitant with CMV disease, four (13%) as non-CMV infection and five (16%) as normal or unspecific. The second GI biopsies diagnosed GVHD in nine (29%) cases, three of which had not exhibited histological signs of GVHD in the first biopsy. Of the remaining cases, the second endoscopy diagnosed GVHD concomitant with CMV disease in four cases (13%), mucosal regenerative changes post-GVHD in five cases (16%) and CMV disease in four cases (13%); normal or unspecific findings were observed in nine cases (29%). The histological diagnoses of the third endoscopic biopsies revealed that one patient had active GVHD, four patients had mucosal regenerative changes post-GVHD, two patients had CMV disease, and one patient had unspecific inflammatory changes. One patient was normal. In two patients, a diagnosis of intestinal toxicity by MMF was done based on clinical suspicion and absence of conclusive data of intestinal GVHD or infection. None of them received additional immunossupresive drugs and both died, one due to severe neurotoxicity to tacrolimus and, one due to thrombotic thrombocytopenic microangiopathy.
The positive predictive value, sensitivity and specificity with which the first endoscopy diagnosed GVHD relative to the histological data were 77, 77 and 44%, respectively. For the second endoscopy, these values were 50, 92 and 33%, respectively. Grades of 2-3 during the first and second endoscopies correctly identified 72% (13/18) and 50% (10/20) of the biopsies that were classified histologically as GVHD, respectively.
The histological findings of the second/third endoscopic biopsies differed from the findings in the first biopsy in 22 of the 31 patients (71%) ( Table 1) . Two examples Serial gastrointestinal endoscopies after allo-SCT C Martínez et al are shown in Figure 1 . In the 22 patients whose initial histological findings revealed GVHD, the second biopsies revealed persistence of GVHD with or without CMV disease in 10 patients, CMV disease without histological evidence of GVHD in four, and resolved GVHD in eight.
In four patients who showed persistence of GVHD on the second biopsy, the third biopsy indicated resolution of the disease despite the persistence of diarrhea. Although most patients who were negative for CMV antigenemia and/or CMV-PCR had no signs of CMV disease in the GI biopsies, in seven of the 73 endoscopies, CMV cytopathic changes and positive immunostaining were observed on the biopsies despite the CMV antigenemia and/or PCR blood data being negative. Fifteen patients were positive for CMV antigenemia or CMV PCR at least once during the study period.
After diagnosis of GI GVHD on first endoscopy, all patients received prednisone 2 mg/kg/day. The results of the second and/or third endoscopies induced a change in the management of the patient in 77% of the cases; this change consisted of increasing (n ¼ 10) or decreasing (n ¼ 13) the immunosuppressive treatment and/or adding specific treatment for a coexisting infectious disease (n ¼ 9). Those patients with diagnoses of active GVHD on second or third endoscopies were treated in accordance with the ongoing trial at our institution with ATG (n ¼ 5), MSCs (n ¼ 3), campath-1-H (n ¼ 1) or etanercept (n ¼ 1).
For the patients who were diagnosed with GVHD on the basis of the first GI endoscopy and biopsy, the endoscopic grades were assessed to determine whether greater mucosal injury was associated with an increased likelihood of persistent GVHD or CMV infection. However, there was no statistical association between endoscopic grades 2-3 on the first endoscopy and the diagnosis of histologically active GVHD on the second evaluation (P ¼ 0.57). However, there was a trend for grade 2-3 endoscopic findings to associate with CMV-positive immunostaining on the second evaluation (P ¼ 0.079).
Three and one of the patients had adenovirus and rotavirus Ags in the stool, respectively. There was also one case of positivity for Clostridium difficile toxin. Campylobacter jejuni could be cultured from another case.
Twenty-nine patients died after a median time from first endoscopy of 71 days (range 14-703) ( Table 3) . Twelve patients (41%) died early within the first 3 months and 17 (59%) died more than 3 months after first endoscopy. Main causes of death were infection (48%) and GVHD (24%) ( Table 3) .
Discussion
To diagnose lower GI GVHD and to exclude other diagnoses, it is generally recommended that endoscopy and biopsy are performed. However, little information exists regarding the role of serial intestinal endoscopic examinations in patients with persistent symptoms. Our data support the notion that when an allografted patient who has been or is being treated for biopsy-proven GI GVHD develops new intestinal symptoms or fails to respond to therapy, restaging of the pathological process affecting the gut should be performed. Serial intestinal endoscopic and histological examinations help to differentiate the persistence of GVHD from intestinal infection, the coexistence of both and secondary mucosal atrophy. In our study, these findings prompted therapeutic changes in a significant proportion of the patients; these changes include adding or avoiding second line treatment for GVHD and/ or adding specific infectious disease therapy.
The endoscopic findings of GI GVHD range from normal to extensive edema and mucosal sloughing. 13 Whether these findings can predict the histological diagnosis and grade of GI GVHD remains controversial. [13] [14] [15] [16] For example, normal endoscopic examinations have been reported in up to 21% of patients with histologically confirmed acute GVHD. 14, 17 Moreover, in a study by Ross et al. that analyzed 112 patients who had simultaneous endoscopic biopsies of the stomach, duodenum and rectosigmoid within the first 100 days after allo-SCT, no association between the degree of mucosal injury and the presence of GVHD was found for any site. 15 In fact, a high proportion of patients with GVHD had normal endoscopic findings (58-62%). However, another study has reported that endoscopic grading correctly identified 80% of the biopsies that were classified histologically as GVHD grades 1-2, while it correctly identified 100% of those biopsies classified as GVHD grades 3-4. 16 The discrepancies between these studies could be explained by differences in the timing of endoscopic examination: those studies that failed to find a correlation between the endoscopic and histological findings performed endoscopy much earlier than the study that did detect a correlation. Supporting this is that in our series, 5 (23%) patients had a normal first endoscopic examination together with histologically confirmed acute GVHD whereas on the second endoscopy, only one of the 31 (3%) patients had a normal endoscopic finding together with a histological diagnosis of GVHD. Notably, on the first and second endoscopies, endoscopic grades of 2-3 correctly identified 72 and 50% of the GVHD-classified biopsies, respectively. This is because a significant proportion of patients with moderate to severe mucosal injury on the second endoscopic evaluation had non-GVHD histological diagnoses such as CMV disease, mucosal atrophy post-GVHD, or normal/unspecific inflammatory mucosa. This meant that the positive predictive value and specificity with which the second endoscopy could diagnose GVHD were lower than for the first endoscopy (50 vs 77%, and 33 vs 44%, respectively). Moreover, there was no association between the extent of mucosal injury on the first endoscopy and the likelihood of GVHD persistence on the subsequent endoscopic examination.
Steroid therapy for moderate-to-severe GVHD has been recognized as a main risk factor for the development of CMV infection and disease. 18 We found that 27% of this group of patients developed GI CMV disease, as determined by the symptoms and endoscopic and histological findings of the second examination, and that endoscopic grades of 2-3 on the first endoscopy tended to associate with subsequent intestinal CMV disease. This suggests that along with steroid treatment, the presence of moderate to severe GI mucosal damage may increase the risk of GI CMV disease.
In our study, although 58% of the patients had cutaneous GVHD at some point after allo-SCT, only 22-33% of these patients had active cutaneous disease at the time they developed GI symptoms. This may reflect a higher response rate by skin GVHD to steroid therapy. Alternatively, it may reflect a possible higher incidence of isolated GI GVHD in patients who received alloRIC. Therefore, the absence of skin GVHD in a patient whose GI symptoms persist cannot be used to rule out GI GVHD. Supporting this are reports of GI GVHD in the absence of skin involvement; indeed, it has been suggested that GI symptoms without skin lesions are an increasingly common presentation of GVHD.
2,19
In summary, our data show that the persistence of GI symptoms after a first diagnosis of GVHD based on endoscopic and histological findings does not necessarily mean treatment has failed, as subsequent endoscopic examinations reveal the frequent development of other GI pathological events, such as CMV disease, mucosal atrophy post-GVHD and the coexistence of GVHD and CMV, all of which are clinical situations that require different therapeutic approaches. Indeed, normal/unspecific inflammatory mucosa can sometimes be observed despite the persistence of GI symptoms.
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